NovoCure Ltd

038

Company Profile

  • Business description

    NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

  • Contact

    Grenville Street
    No. 4 The Forum, Second Floor
    St. HelierJE2 4UF
    JEY

    T: +44 1534756700

    E: [email protected]

    https://www.novocure.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Devices

    Fiscal Year End

    31 December 2026

    Employees

    1,605

Stocks News & Analysis

stocks

SK Hynix Earnings: We raise fair value estimate on strong AI memory demand

Shares jumped 9% after earnings, as stronger AI memory prices boosted the chipmaker’s outlook.
stocks

Meta shares are down 12% since earnings. Is the stock a buy?

Concerns about equity sales to finance AI investments have pressured shares.
stocks

SpaceX earnings: We raise our fair value estimate on scaling data centres, but is the stock a buy?

AI data center revenue is growing fast, but questions about durability remain.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,012.6041.200.46%
CAC 407,965.3578.390.99%
DAX 4025,957.30253.280.99%
Dow JONES (US)52,475.1097.530.19%
FTSE 10010,732.3237.820.35%
HKSE22,958.65136.18-0.59%
NASDAQ26,549.8572.040.27%
Nikkei 22564,659.47705.281.10%
NZX 50 Index13,710.1718.840.14%
S&P 5007,743.9821.380.28%
S&P/ASX 2008,891.8044.500.50%
SSE Composite Index3,651.4330.04-0.82%

Market Movers